A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjects

• Váldodahkkit: Sibel Ucpinar (Dahkki), Borje Darpo (Dahkki), Ann Neale (Dahkki), Philip Nunn (Dahkki), Jin Shu (Dahkki), Katherine A. Chu (Dahkki), Marianne Kavanagh (Dahkki), Hongqi Xue (Dahkki), Pasit Phiasivongsa (Dahkki), Dolca Thomas (Dahkki), Patrick F. Smith (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2022-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract This study aimed to define the clinically relevant supratherapeutic dose of rilzabrutinib, an oral Bruton tyrosine kinase (BTK) inhibitor, and evaluate potential effects of therapeutic and supratherapeutic exposures on cardiac repolarization in healthy subjects. This was a two‐part phase I...